glp-1 lawsuit in michigan Lawyer glp-1 digestive blockage lawsuit in
Description
doi:10.3390/diseases12090204 24
Common adverse events included diarrhea, vomiting, and constipation (more common for those on the highest dose)
Tas1Rs in -cells are implicated in insulin secretion and therefore also mediating the homeostatic response to food intake
The hope: Retatrutide may become an important future option if FDA review supports approval
PMCID: PMC11372654
Recommendation 7-3) If the target blood glucose level is not achieved using GLP-1 RA or basal insulin treatment, initiate intensive insulin therapy
